Michael J. LaBarre - Feb 27, 2023 Form 4/A - Amendment Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
SVP, CHIEF TECHNICAL OFFICER
Signature
/s/ James Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Feb 27, 2023
Transactions value $
-$92,919
Form type
4/A - Amendment
Date filed
4/19/2023, 06:01 PM
Date Of Original Report
Feb 28, 2023
Previous filing
Feb 21, 2023
Next filing
Apr 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $54.9K +2.98K +2.1% $18.41 145K Feb 27, 2023 Direct F1, F2
transaction HALO Common Stock Sale -$148K -2.98K -2.06% $49.55 142K Feb 27, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise $0 -2.98K -7.37% $0.00 37.5K Feb 27, 2023 Common Stock 2.98K $18.41 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 This amendment is being filed to include the option exercise information in Tables I and II and to update the information in Table I, Column 5.
F3 Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.36 to $49.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.